Intrinsic Imaging Awarded Phase II Trial for Metastatic Pancreatic Cancer

Phase II trial services evaluate metastatic pancreatic cancer and advanced colorectal cancer treatment response using RECIST and PERCIST imaging criteria.

Bolton, MA / San Antonio, TX

Bolton, MA / San Antonio, TX — June 20, 2012 — Intrinsic Imaging, an ISO 9001 certified and GAMP 5 medical imaging core lab specializing in providing imaging core lab services for clinical trials, announces today that it was recently awarded a Phase II efficacy trial for Metastatic Pancreatic Cancer.

This clinical research study utilizes a novel investigational biologic treatment for patients with any stage of metastatic pancreatic adenocarcinoma or advanced colorectal cancer that no longer responds to standard therapies. During this trial, Intrinsic Imaging will study treatment response of the patient's cancer by evaluating images using Response Evaluation Criteria in Solid Tumors (RECIST). Intrinsic Imaging will also provide qualitative and quantitative assessments of metabolic tumor response using PET Response Criteria in Solid Tumors (PERCIST).

"The award of this critical Phase II trial to Intrinsic Imaging is a testament of the continued trust and respect we have earned from Sponsors as a preferred imaging core lab for clinical trials." said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging. "We are very pleased to contribute our therapeutic expertise towards the development of this novel ground breaking treatment for Metastatic Pancreatic Cancer."

Intrinsic Imaging's team of more than sixty board-certified diagnostic radiologists have sub-specialization in all therapeutic areas including, but not limited to, Cardiovascular and Thoracic, Central Nervous System, Gastrointestinal & Genitourinary, Musculoskeletal, Medical Device, and Oncology. The Oncology team consists of 12 oncology trained board-certified radiologists and 8 board-certified interventional oncology radiologists who have in-depth experience in pancreatic, colorectal, breast, lung, ovarian and prostate cancer, among others.

About Intrinsic Imaging, LLC

Intrinsic Imaging is an ISO certified medical imaging CRO and imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, III medical device trials. Intrinsic Imaging is also a world leader in conducting Artificial Intelligence studies. With its team of more than 750 board-certified and fellowship-trained physicians, Intrinsic Imaging's team has sub-specialization in all therapeutic areas, including Cardiovascular, Central Nervous System,Gastroenterology, Musculoskeletal, Oncology and Ophthalmology. Certified by the British Standards Institution (BSI), Intrinsic Imaging is the only company in the world to hold five ISO certifications specifically for providing imaging core lab services on clinical trials. For more information, please visit www.IntrinsicImaging.com.

Contact:

Intrinsic Imaging, LLC
580 Main St., Suite 210
Bolton, MA, 01740, USA
+1 978-616-4650
Contact@IntrinsicImaging.com